annual cash & cash equivalents:
$51.37M+$20.20M(+64.82%)Summary
- As of today (September 17, 2025), AVDL annual cash & cash equivalents is $51.37 million, with the most recent change of +$20.20 million (+64.82%) on December 31, 2024.
- During the last 3 years, AVDL annual cash & cash equivalents has risen by +$663.00 thousand (+1.31%).
- AVDL annual cash & cash equivalents is now -53.14% below its all-time high of $109.62 million, reached on December 31, 2003.
Performance
AVDL Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$81.55M+$15.06M(+22.66%)Summary
- As of today (September 17, 2025), AVDL quarterly cash & cash equivalents is $81.55 million, with the most recent change of +$15.06 million (+22.66%) on June 1, 2025.
- Over the past year, AVDL quarterly cash & cash equivalents has increased by +$10.16 million (+14.24%).
- AVDL quarterly cash & cash equivalents is now -65.82% below its all-time high of $238.55 million, reached on June 30, 2020.
Performance
AVDL quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
AVDL Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +64.8% | +14.2% |
| 3 y3 years | +1.3% | -21.7% |
| 5 y5 years | +425.6% | -65.8% |
AVDL Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -30.6% | +64.8% | -49.2% | +23.9% |
| 5 y | 5-year | -30.6% | +425.6% | -65.8% | +23.9% |
| alltime | all time | -53.1% | +4946.3% | -65.8% | +6695.6% |
AVDL Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $81.55M(+22.7%) |
| Mar 2025 | - | $66.48M(-9.9%) |
| Dec 2024 | $51.37M(+64.8%) | $73.78M(+12.1%) |
| Sep 2024 | - | $65.81M(-7.8%) |
| Jun 2024 | - | $71.38M(-19.6%) |
| Mar 2024 | - | $88.79M(-15.5%) |
| Dec 2023 | $31.17M(-57.9%) | $105.11M(-31.4%) |
| Sep 2023 | - | $153.18M(-4.6%) |
| Jun 2023 | - | $160.51M(+59.0%) |
| Mar 2023 | - | $100.92M(+4.6%) |
| Dec 2022 | $73.98M(+45.9%) | $96.50M(-9.4%) |
| Sep 2022 | - | $106.47M(+2.3%) |
| Jun 2022 | - | $104.12M(-15.7%) |
| Mar 2022 | - | $123.48M(-21.5%) |
| Dec 2021 | $50.71M(-29.3%) | $157.22M(-13.2%) |
| Sep 2021 | - | $181.09M(-10.7%) |
| Jun 2021 | - | $202.84M(-1.0%) |
| Mar 2021 | - | $204.97M(-7.4%) |
| Dec 2020 | $71.72M(+633.8%) | $221.40M(-4.4%) |
| Sep 2020 | - | $231.58M(-2.9%) |
| Jun 2020 | - | $238.55M(+110.2%) |
| Mar 2020 | - | $113.48M(+76.9%) |
| Dec 2019 | $9.77M(+4.8%) | $64.16M(-11.5%) |
| Sep 2019 | - | $72.45M(-8.6%) |
| Jun 2019 | - | $79.26M(-0.7%) |
| Mar 2019 | - | $79.85M(-20.1%) |
| Dec 2018 | $9.32M(-43.7%) | $99.92M(-20.2%) |
| Sep 2018 | - | $125.26M(-14.8%) |
| Jun 2018 | - | $147.11M(-25.8%) |
| Mar 2018 | - | $198.18M(+110.7%) |
| Dec 2017 | $16.56M(-57.8%) | $94.08M(-18.6%) |
| Sep 2017 | - | $115.61M(-33.5%) |
| Jun 2017 | - | $173.80M(-3.0%) |
| Mar 2017 | - | $179.21M(+16.2%) |
| Dec 2016 | $39.22M(-39.7%) | $154.19M(+3.0%) |
| Sep 2016 | - | $149.67M(-3.4%) |
| Jun 2016 | - | $154.86M(-3.2%) |
| Mar 2016 | - | $159.95M(+10.5%) |
| Dec 2015 | $65.06M(+63.6%) | $144.80M(+27.9%) |
| Mar 2015 | - | $113.17M(+21.9%) |
| Dec 2014 | $39.76M | $92.83M(+21.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2014 | - | $76.50M(-1.7%) |
| Jun 2014 | - | $77.86M(-6.8%) |
| Mar 2014 | - | $83.52M(+1086.9%) |
| Dec 2013 | $6.64M(+142.0%) | $7.04M(-24.2%) |
| Sep 2013 | - | $9.28M(-4.6%) |
| Jun 2013 | - | $9.72M(-36.7%) |
| Mar 2013 | - | $15.37M(+67.9%) |
| Dec 2012 | $2.74M(-20.7%) | $9.15M(-77.5%) |
| Dec 2011 | $3.46M(-57.8%) | - |
| Dec 2010 | $8.18M(-6.1%) | - |
| Dec 2009 | $8.72M(-67.7%) | - |
| Dec 2008 | $27.02M(+2.7%) | - |
| Dec 2007 | $26.31M(-49.2%) | - |
| Sep 2007 | - | $40.76M(-13.2%) |
| Jun 2007 | - | $46.97M(-10.9%) |
| Mar 2007 | - | $52.72M(-23.8%) |
| Dec 2006 | $51.83M(+4991.1%) | - |
| Jun 2006 | - | $69.14M(-8.1%) |
| Mar 2006 | - | $75.21M(-15.9%) |
| Dec 2005 | $1.02M(-77.8%) | - |
| Sep 2005 | - | $89.42M(-12.8%) |
| Jun 2005 | - | $102.59M(-5.7%) |
| Mar 2005 | - | $108.83M(+3.3%) |
| Dec 2004 | $4.59M(-95.8%) | $105.37M(+10.1%) |
| Sep 2004 | - | $95.70M(-5.1%) |
| Jun 2004 | - | $100.85M(-4.3%) |
| Mar 2004 | - | $105.44M(-3.8%) |
| Dec 2003 | $109.62M(+654.6%) | $109.62M(+396.5%) |
| Sep 2003 | - | $22.08M(+89.5%) |
| Jun 2003 | - | $11.65M(-18.6%) |
| Mar 2003 | - | $14.32M(-1.4%) |
| Dec 2002 | $14.53M(+173.6%) | $14.53M(-0.7%) |
| Sep 2002 | - | $14.62M(+175.4%) |
| Dec 2001 | $5.31M(-47.6%) | $5.31M(-47.6%) |
| Dec 2000 | $10.14M(+94.6%) | $10.14M(+94.6%) |
| Dec 1999 | $5.21M(-28.4%) | $5.21M(-28.4%) |
| Dec 1998 | $7.28M(+91.5%) | $7.28M(+21.3%) |
| Mar 1998 | - | $6.00M(+57.9%) |
| Dec 1997 | $3.80M(-75.5%) | $3.80M(-75.5%) |
| Dec 1996 | $15.50M | $15.50M(+1191.7%) |
| Mar 1996 | - | $1.20M |
FAQ
- What is Avadel Pharmaceuticals plc annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Avadel Pharmaceuticals plc?
- What is Avadel Pharmaceuticals plc annual cash & cash equivalents year-on-year change?
- What is Avadel Pharmaceuticals plc quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Avadel Pharmaceuticals plc?
- What is Avadel Pharmaceuticals plc quarterly cash & cash equivalents year-on-year change?
What is Avadel Pharmaceuticals plc annual cash & cash equivalents?
The current annual cash & cash equivalents of AVDL is $51.37M
What is the all time high annual cash & cash equivalents for Avadel Pharmaceuticals plc?
Avadel Pharmaceuticals plc all-time high annual cash & cash equivalents is $109.62M
What is Avadel Pharmaceuticals plc annual cash & cash equivalents year-on-year change?
Over the past year, AVDL annual cash & cash equivalents has changed by +$20.20M (+64.82%)
What is Avadel Pharmaceuticals plc quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of AVDL is $81.55M
What is the all time high quarterly cash & cash equivalents for Avadel Pharmaceuticals plc?
Avadel Pharmaceuticals plc all-time high quarterly cash & cash equivalents is $238.55M
What is Avadel Pharmaceuticals plc quarterly cash & cash equivalents year-on-year change?
Over the past year, AVDL quarterly cash & cash equivalents has changed by +$10.16M (+14.24%)